Historique de carrière de Donald C. Fresne
Anciens postes connus de Donald C. Fresne
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Egenix, Inc.
 Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Directeur/Membre du Conseil | - | 17/04/2020 |
| Directeur Général | 25/07/2011 | 19/12/2014 | |
| President | 25/07/2011 | 19/12/2014 | |
Epigen, Inc.
 Epigen, Inc. Medical SpecialtiesHealth Technology Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991. | Président | 05/03/2010 | 23/09/2010 |
| President | 05/03/2010 | 23/09/2010 |
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| President | 2 |
| Chairman | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Epigen, Inc.
Epigen, Inc. Medical SpecialtiesHealth Technology Epigen, Inc. develops products to monitor, diagnose and treat cancer n a more effective, less expensive and less invasive manner than other products currently available. The company is in the process of completing the development of its in-vitro blood test, a confirmatory test for prostate cancer. This employs the use of the HC Antigen. It was founded on April 24, 1991. | Health Technology |
Egenix, Inc.
Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Health Technology |
- Bourse
- Insiders
- Donald C. Fresne
- Expérience
